Quantcast

Latest Lorus Therapeutics Inc. Stories

2014-08-19 16:29:20

TORONTO, Aug. 19, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company") today announced voting results from the Company's annual and special meeting of shareholders held on August 19th in Toronto (the "Meeting"). The Company is pleased to announce that all of the nominees listed in the management proxy circular dated July 15, 2014 were elected as directors. Each of the directors was elected by a majority of the votes cast by shareholders present at...

2014-07-28 08:28:49

TORONTO, July 28, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) today announced that the Food and Drug Administration (FDA) completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma. Clearance of the IND allows Lorus to initiate a Phase 1b, multi-center, open-label,...

2014-07-15 16:27:49

TORONTO, July 15, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) today reported financial results for the year and three months ended May 31, 2014 and provided an overview of fiscal 2014 highlights and recent accomplishments. Unless specified otherwise, all amounts are in Canadian dollars. Net loss and comprehensive loss for the year ended May 31, 2014 increased to $10.6 million ($0.17 per share) compared to $5.6 million ($0.13 per share) for the year ended May 31, 2013....

2014-07-10 08:27:23

TORONTO, July 10, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) today announced that the Company will release its fourth quarter and year end 2014 financial results on Tuesday, July 15, 2014 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. EDT to discuss the financial results. Participants can access the conference call by dialing 1-888-231-8191 (North American toll free number) or 647-427-7450 (local). The...

2014-06-10 08:30:10

TORONTO, June 10, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) (Lorus") is pleased to announce that 18.5 million common share purchase warrants and 1.2 million broker warrants expiring on June 8, 2014 and originally issued in connection with a financing completed in June 2012, have been exercised recently, raising approximately $8.7 million in net proceeds since mid-April. The proceeds will be used for working capital and general corporate purposes. "I'm delighted by...

2008-10-09 09:00:52

Lorus Therapeutics Inc. (Lorus) (TSX: LOR)(AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three months ended August 31, 2008. Unless specified otherwise, all amounts are in Canadian dollars. JUNE 1, 2008 TO DATE HIGHLIGHTS: - Completed a rights offering to eligible shareholders raising net proceeds of $3.2 million. - Successfully...

2008-07-29 09:00:24

TORONTO, ONTARIO--(Marketwire - July 29, 2008) - Lorus Therapeutics Inc. (TSX:LOR)(AMEX:LRP) ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the allowance of a new patent from the United States Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040. The patent, which was issued this month as U.S. Patent No. 7,405,205, protects methods of treating...

2008-07-21 08:45:08

TORONTO, July 21 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and twelve months ended May 31, 2008. Unless specified otherwise, all amounts are in Canadian dollars. 2008 HIGHLIGHTS - Initiation of GLP toxicology studies for Lorus' lead anticancer small molecule drug...

2008-07-09 09:00:13

TORONTO, July 9 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced progress made in the Virulizin(R) development program, including the publication of two research studies on the Virulizin(R) mode of action and the issuance of a new patent for Virulizin(R) in Mexico....


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related